A pioneering clinical trial investigating medicinal cannabis as a potential treatment for people living with Tourette syndrome will be conducted by Wesley Medical Research, with the cannabis supply facilitated by Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney.
The trial is the first of its kind in Australia and will take place at Wesley Medical Research in Brisbane led by Chief Investigator and neuropsychiatrist Dr Philip Mosley.
Participants will complete two periods of treatment with either a medicinal cannabis drug or a placebo, with both investigators and participants unaware of treatment status until the end of the trial.
Participants in the clinical trial at Wesley Medical Research will complete two six-week "crossover" periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.
Participants in the clinical trial at Wesley Medical Research will complete two six-week "crossover" periods of treatment with active drug or placebo, with both participants and investigators unaware of treatment status until the trial is complete.